Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies

Tuberculosis

Volumn 88, Issue SUPPL. 1, 2008, Pages

  Basaraba, Randall J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Animal models; Drug therapy; Pathology; Tuberculosis

Indexed keywords

IRON; TUBERCULOSTATIC AGENT;

ANIMAL MODEL; ARTICLE; BIOFILM; CALCIFICATION; COMPARATIVE STUDY; DRUG RESEARCH; EXTRAPULMONARY TUBERCULOSIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SPECIES DIFFERENCE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NECROSIS; SPECIES SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 50349094162     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70035-0     Document Type: Article

References (155)

1. Laurenzi M., Ginsberg A., and Spigelman M. Challenges associated with current and future TB treatment?. Infect Disord Drug Targets 7 (2007) 105-119
2. Ginsberg A.M., and Spigelman M. Challenges in tuberculosis drug research and development?. Nat Med 13 (2007) 290-294
3. Cardona P.J., Llatjos R., Gordillo S., Diaz J., Vinado B., Ariza A., and Ausina V. Towards a 'human-like' model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Myco-bacterium tuberculosis?. Scand J Immunol 53 (2001) 65-71
4. Guirado E., Gordillo S., Gil O., Diaz J., Tapia G., Vilaplana C., Ausina V., and Cardona P.J. Intragranulomatous necrosis in pulmonary granulomas is not related to resistance against Mycobacterium tuberculosis infection in experimental murine models induced by aerosol?. Int J Exp Pathol 87 (2006) 139-149
5. Chackerian A.A., Alt J.M., Perera T.V., Dascher C.C., and Behar S.M. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity?. Infect Immun 70 (2002) 4501-4509
6. Mestas J., and Hughes C.C. Of mice and not men: differences between mouse and human immunology?. J Immunol 172 (2004) 2731-2738
7. Shoda L.K., Young D.L., Ramanujan S., Whiting C.C., Atkinson M.A., Bluestone J.A., Eisenbarth G.S., Mathis D., Rossini A.A., Campbell S.E., Kahn R., and Kreuwel H.T. A comprehensive review of interventions in the NOD mouse and implications for translation?. Immunity 23 (2005) 115-126
8. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., Macleod M., Mignini L.E., Jayaram P., and Khan K.S. Comparison of treatment effects between animal experiments and clinical trials: systematic review?. Bmj 334 (2007) 197
9. Fox W. On the Artificial Production of Tubercle in the Lower Animals (1868), MacMillan and Co., London
10. Klein E.E. Contributions to the Normal and Pathological Anatomy of the Lymphatic System of the Lungs?. Proceedings of the Royal Society of London 22 1873-1874 (1874) 133-145
11. Koch R. Die aetiologie der tuberculose?. Berl Klinische Wochenschr 19 (1882) 221-230
12. Sanderson JB. On the communicability of Tubercle by Inoculation. Report of the Medical Officer 1867.
13. Lefford M.J., McGregor D.D., and Mackaness G.B. Immune response to Mycobacterium tuberculosis in rats?. Infect Immun 8 (1973) 182-189
14. Lin P.L., Pawar S., Myers A., Pegu A., Fuhrman C., Reinhart T.A., Capuano S.V., Klein E., and Flynn J.L. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques?. Infect Immun 74 (2006) 3790-3803
15. Lurie M.B. The use of the rabbit in experimental chemotherapy of tuberculosis?. Ann N Y Acad Sci 52 (1949) 627-636
16. Orme I. Cellular and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection. Novartis Found Symp 217 (1998) 112-117 discussion 117-119.
17. Schmidt L.H. Studies on the antituberculous activity of ethambutol in monkeys?. Ann N Y Acad Sci 135 (1966) 747-758
18. Schmidt L.H., Hoffman R., and Hughes H.B. The toxicity of isoniazid for the rhesus monkey?. Am Rev Tuberc 67 (1953) 798-807
19. Smith D.W., and Harding G.E. Animal model of human disease. Pulmonary tuberculosis. Animal model: Experimental airborne tuberculosis in the guinea pig?. Am J Pathol 89 (1977) 273-276
20. Wolf R.H., Gibson S.V., Watson E.A., and Baskin G.B. Multidrug chemotherapy of tuberculosis in rhesus monkeys?. Lab Anim Sci 38 (1988) 25-33
21. Balasubramanian V., Wiegeshaus E.H., and Smith D.W. Mycobacterial infection in guinea pigs?. Immunobiolo 191 (1994) 395-401
22. Dorman S.E., Hatem C.L., Tyagi S., Aird K., Lopez-Molina J., Pitt M.L., Zook B.C., Dannenberg Jr. A.M., Bishai W.R., and Manabe Y.C. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits?. Infect Immun 72 (2004) 1700-1705
23. Elwood R.L., Wilson S., Blanco J.C., Yim K., Pletneva L., Nikonenko B., Samala R., Joshi S., Hemming V.G., and Trucksis M. The American cotton rat: a novel model for pulmonary tuberculosis?. Tuberculosis (Edinb) 87 (2007) 145-154
24. Flynn J.L., Copper A.M., and Bishai W. Animal Models of Tuberculosis (2005), ASM Press, Washington, D.C.
25. Flynn J.L. Lessons from experimental Mycobacterium tuberculosis infections?. Microbes Infect 8 (2006) 1179-1188
26. Flynn J.L., Capuano S.V., Croix D., Pawar S., Myers A., Zinovik A., and Klein E. Non-human primates: a model for tuberculosis research?. Tuberculosis (Edinb) 83 (2003) 116-118
27. Gupta U.D., and Katoch V.M. Animal models of tuberculosis?. Tuberculosis (Edinb) 85 (2005) 277-293
28. Helke K.L., Mankowski J.L., and Manabe Y.C. Animal models of cavitation in pulmonary tuberculosis?. Tuberculosis (Edinb) 86 (2006) 337-348
29. McMurray D.N. A nonhuman primate model for preclinical testing of new tuberculosis vaccines?. Clin Infect Dis 30 Suppl 3 (2000) S210-S212
30. McMurray D.N. Disease model: pulmonary tuberculosis?. Trends Mol Med 7 (2001) 135-137
31. Smith D.W., and Wiegeshaus E.H. What animal models can teach us about the pathogenesis of tuberculosis in humans?. Rev Infect Dis 11 Suppl 2 (1989) S385-S393
32. Kirchheimer W.F., and Youmans G.P. The in vivo and in vitro effect of streptomycin on streptomycin-resistant tubercle bacilli?. Am Rev Tuberc 66 (1952) 486-496
33. Youmans G.P. The use of the mouse for the testing of chemotherapeutic agents against Mycobacterium tuberculosis?. Ann N Y Acad Sci 52 (1949) 662-670
34. Lenaerts A.J., Gruppo V., Brooks J.V., and Orme I.M. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice?. Antimicrob Agents Chemother 47 (2003) 783-785
35. Lenaerts A.M., Chase S.E., Chmielewski A.J., and Cynamon M.H. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice?. Antimicrob Agents Chemother 43 (1999) 2356-2360
36. Lenaerts A.M., Chase S.E., and Cynamon M.H. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model?. Antimicrob Agents Chemother 44 (2000) 3167-3168
37. Sugawara I., Udagawa T., and Yamada H. Rat neutrophils prevent the development of tuberculosis?. Infect Immun 72 (2004) 1804-1806
38. Sugawara I., Yamada H., and Mizuno S. Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats?. Tohoku J Exp Med 204 (2004) 135-145
39. Sugawara I., Yamada H., and Mizuno S. Pathological and immunological profiles of rat tuberculosis?. Int J Exp Pathol 85 (2004) 125-134
40. Sugawara I., Yamada H., and Mizuno S. Nude rat (F344/N-rnu) tuberculosis?. Cell Microbiol 8 (2006) 661-667
41. Canetti G. The Tubercle Bacillus in the Pulmonary Lesion of Man; Histobacteriology and its bearing on the therapy of pulmonary tuberculosis. 2 edn. (1955), Springer Publishing Company, Inc, New York
42. Cardona P.J., Llatjos R., Gordillo S., Diaz J., Ojanguren I., Ariza A., and Ausina V. Evolution of granulomas in lungs of mice infected aerogenically with Mycobacterium tuberculosis?. Scand J Immunol 52 (2000) 156-163
43. Converse P.J., Dannenberg Jr. A.M., Estep J.E., Sugisaki K., Abe Y., Schofield B.H., and Pitt M.L. Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli?. Infect Immun 64 (1996) 4776-4787
44. Ordway D., Palanisamy G., Henao-Tamayo M., Smith E.E., Shanley C., Orme I.M., and Basaraba R.J. The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig?. J Immunol 179 (2007) 2532-2541
45. Rhoades E.R., Frank A.A., and Orme I.M. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis?. Tuber Lung Dis 78 (1997) 57-66
46. Maglione P.J., Xu J., and Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis?. J Immunol 178 (2007) 7222-7234
47. Ulrichs T., and Kaufmann S.H. New insights into the function of granulomas in human tuberculosis?. J Pathol 208 (2006) 261-269
48. Ulrichs T., Kosmiadi G.A., Trusov V., Jorg S., Pradl L., Titukhina M., Mishenko V., Gushina N., and Kaufmann S.H. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung?. J Pathol 204 (2004) 217-228
49. Ulrichs T., Lefmann M., Reich M., Morawietz L., Roth A., Brinkmann V., Kosmiadi G.A., Seiler P., Aichele P., Hahn H., Krenn V., Gobel U.B., and Kaufmann S.H. Modified immunohistological staining allows detection of Ziehl-Neelsennegative Mycobacterium tuberculosis organisms and their precise localization in human tissue?. J Pathol 205 (2005) 633-640
50. Atomiya A.N., Uip D.E., and Leite O.H. Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient?. Braz J Infect Dis 6 (2002) 29-39
51. Chan J., Tian Y., Tanaka K.E., Tsang M.S., Yu K., Salgame P., Carroll D., Kress Y., Teitelbaum R., and Bloom B.R. Effects of protein calorie malnutrition on tuberculosis in mice?. Proc Natl Acad Sci U S A 93 (1996) 14857-14861
52. Gangaidzo I.T., Moyo V.M., Mvundura E., Aggrey G., Murphree N.L., Khumalo H., Saungweme T., Kasvosve I., Gomo Z.A., Rouault T., Boelaert J.R., and Gordeuk V.R. Association of pulmonary tuberculosis with increased dietary iron?. J Infect Dis 184 (2001) 936-939
53. Hill P.C., Jackson-Sillah D., Donkor S.A., Otu J., Adegbola R.A., and Lienhardt C. Risk factors for pulmonary tuberculosis: a clinic-based case control study in The Gambia?. BMC Public Health 19 (2006) 156
54. Horwitz O. The risk of tuberculosis in different groups of the general population?. Scand J Respir Dis Suppl 72 (1970) 59-60
55. Lienhardt C., Sillah J., Fielding K., Donkor S., Manneh K., Warndorff D., Bennett S., and McAdam K. Risk factors for tuberculosis infection in children in contact with infectious tuberculosis cases in the Gambia, West Africa?. Pediatrics 111 (2003) 608-614
56. Martens G.W., Arikan M.C., Lee J., Ren F., Greiner D., and Kornfeld H. Tuberculosis susceptibility of diabetic mice?. Am J Respir Cell Mol Biol 37 (2007) 518-524
57. McMurray D.N., and Yetley E.A. Immune responses in malnourished guinea pigs?. J Nutr 112 (1982) 167-174
58. McMurray D.N., and Yetley E.A. Cell-mediated immunity in malnourished guinea pigs after Mycobacterium bovis BCG vaccination?. Infect Immun 35 (1982) 909-914
59. Slama K., Chiang C.Y., Enarson D.A., Hassmiller K., Fanning A., Gupta P., and Ray C. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis?. Int J Tuberc Lung Dis 11 (2007) 1049-1061
60. Young J., and O'Connor M.E. Risk factors associated with latent tuberculosis infection in Mexican American children?. Pediatrics 115 (2005) 647-653
61. Ridley D.S., and Ridley M.J. Rationale for the histological spectrum of tuberculosis. A basis for classification?. Pathology 19 (1987) 186-192
62. Cardona P.J., Cooper A., Luquin M., Ariza A., Filipo F., Orme I.M., and Ausina V. The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity?. Scand J Immunol 49 (1999) 362-366
63. Kramnik I., Dietrich W.F., Demant P., and Bloom B.R. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis?. Proc Natl Acad Sci U S A 97 (2000) 8560-8565
64. Sugawara I., Yamada H., and Mizuno S. STAT1 knockout mice are highly susceptible to pulmonary mycobacterial infection?. Tohoku J Exp Med 202 (2004) 41-50
65. McMurray D.N. Hematogenous reseeding of the lung in low dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles?. Tuberculosis (Edinb) 83 (2003) 131-134
66. Actor J.K., Olsen M., Jagannath C., and Hunter R.L. Relationship of survival, organism containment, and granuloma formation in acute murine tuberculosis?. J Interferon Cytokine Res 19 (1999) 1183-1193
67. Saunders B.M., and Cooper A.M. Restraining mycobacteria: role of granulomas in mycobacterial infections?. Immunol Cell Biol 78 (2000) 334-341
68. Saunders B.M., Frank A.A., and Orme I.M. Granuloma formation is required to contain bacillus growth and delay mortality in mice chronically infected with Mycobacterium tuberculosis?. Immunology 98 (1999) 324-328
69. Kaplan G., Post F.A., Moreira A.L., Wainwright H., Kreiswirth B.N., Tanverdi M., Ramaswamy S.V., Walther G., Steyn L.M., and Barry C. III, Bekker LG. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity?. Infect Immun 71 (2003) 7099-7108
70. Lenaerts A.J., Hoff D., Aly S., Ehlers S., Andries K., Cantarero L., Orme I.M., and Basaraba R.J. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910?. Antimicrob Agents Chemother 51 (2007) 3338-3345
71. Basaraba R.J., Dailey D.D., McFarland C.T., Shanley C.A., Smith E.E., McMurray D.N., and Orme I.M. Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis?. Tuberculosis (Edinb) 86 (2006) 386-394
72. Dannenberg Jr. A.M. Pathogenesis of Human Pulmonary Tuberculosis; Insights from the rabbit model. 1 edn. (2006), ASM Press, Washington, D.C.
73. Turner O.C., Basaraba R.J., Frank A.A., Orme I.M., and Boros D.L. Granuloma formation in mouse and guinea pig models of experimental tuberculosis. Granulomatous Infections and Inflammations: Cellular and Molecular Mechanisms (2003), ASM Press, Washington D.C. 65-84
74. Smith D.W., Balasubramanian V., and Wiegeshaus E. A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment?. Tubercle 72 (1991) 223-231
75. Turner O.C., Basaraba R.J., and Orme I.M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis?. Infect Immun 71 (2003) 864-871
76. Capuano III S.V., Croix D.A., Pawar S., Zinovik A., Myers A., Lin P.L., Bissel S., Fuhrman C., Klein E., and Flynn J.L. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection?. Infect Immun 71 (2003) 5831-5844
77. Cardona P.J., Gordillo S., Diaz J., Tapia G., Amat I., Pallares A., Vilaplana C., Ariza A., and Ausina V. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis?. Infect Immun 71 (2003) 5845-5854
78. Dhillon J., and Mitchison D.A. Influence of BCG-induced immunity on the bactericidal activity of isoniazid and rifampicin in experimental tuberculosis of the mouse and guinea-pig?. Br J Exp Pathol 70 (1989) 103-110
79. Seiler P., Ulrichs T., Bandermann S., Pradl L., Jorg S., Krenn V., Morawietz L., Kaufmann S.H., and Aichele P. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection?. J Infect Dis 188 (2003) 1326-1331
80. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice?. J Exp Med 178 (1993) 2243-2247
81. Ehlers S., Benini J., Kutsch S., Endres R., Rietschel E.T., and Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium?. Infect Immun 67 (1999) 3571-3579
82. Gil O., Guirado E., Gordillo S., Diaz J., Tapia G., Vilaplana C., Ariza A., Ausina V., and Cardona P.J. Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type?. Microbes Infect 8 (2006) 628-636
83. Hunter R.L., Jagannath C., and Actor J.K. Pathology of post primary tuberculosis in humans and mice: contradiction of long-held beliefs?. Tuberculosis (Edinb) 87 (2007) 267-278
84. Hunter R.L., Olsen M., Jagannath C., and Actor J.K. Trehalose 6,6'-dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice?. Am J Pathol 168 (2006) 1249-1261
85. Hunter R.L., Olsen M.R., Jagannath C., and Actor J.K. Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease?. Ann Clin Lab Sci 36 (2006) 371-386
86. Reiling N., Schneider D., and Ehlers S. Mycobacterium tuberculosis-induced cell death of primary human monocytes and macrophages is not significantly modulated by tumor necrosis factor-targeted biologicals?. J Investig Dermatol Symp Proc 12 (2007) 26-33
87. Appelberg R. T cell regulation of the chronic peritoneal neutrophilia during mycobacterial infections?. Clin Exp Immunol 89 (1992) 120-125
88. Appelberg R. Mycobacterial infection primes T cells and macrophages for enhanced recruitment of neutrophils?. J Leukoc Biol 51 (1992) 472-477
89. Kipnis A., Basaraba R.J., Turner J., and Orme I.M. Increased neutrophil influx but no impairment of protective immunity to tuberculosis in mice lacking the CD44 molecule?. J Leukoc Biol 74 (2003) 992-997
90. Pedrosa J., Saunders B.M., Appelberg R., Orme I.M., Silva M.T., and Cooper A.M. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice?. Infect Immun 68 (2000) 577-583
91. Aly S., Wagner K., Keller C., Malm S., Malzan A., Brandau S., Bange F.C., and Ehlers S. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice?. J Pathol 210 (2006) 298-305
92. Madjdpour C., Jewell U.R., Kneller S., Ziegler U., Schwendener R., Booy C., Klausli L., Pasch T., Schimmer R.C., and Beck-Schimmer B. Decreased alveolar oxygen induces lung inflammation?. Am J Physiol Lung Cell Mol Physiol 284 (2003) L360-L367
93. Tsai M.C., Chakravarty S., Zhu G., Xu J., Tanaka K., Koch C., Tufariello J., Flynn J., and Chan J. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension?. Cell Microbiol 8 (2006) 218-232
94. Taneja N.K., and Tyagi J.S. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis?. J Antimicrob Chemother 60 (2007) 288-293
95. Wayne L.G., and Hayes L.G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence?. Infect Immun 64 (1996) 2062-2069
96. Bacon J., James B.W., Wernisch L., Williams A., Morley K.A., Hatch G.J., Mangan J.A., Hinds J., Stoker N.G., Butcher P.D., and Marsh P.D. The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis?. Tuberculosis (Edinb) 84 (2004) 205-217
97. Balazuc A.M., Lagranderie M., Chavarot P., Pescher P., Roseeuw E., Schacht E., Domurado D., and Marchal G. In vivo efficiency of targeted norfloxacin against persistent, isoniazid-insensitive, Mycobacterium bovis BCG present in the physiologically hypoxic mouse liver?. Microbes Infect 7 (2005) 969-975
98. Woolhiser L., Tamayo M.H., Wang B., Gruppo V., Belisle J.T., Lenaerts A.J., Basaraba R.J., and Orme I.M. In vivo adaptation of the Wayne model of latent tuberculosis?. Infect Immun 75 (2007) 2621-2625
99. Fenhalls G., Stevens L., Moses L., Bezuidenhout J., Betts J.C., Helden P.P., Lukey P.T., and Duncan K. In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions?. Infect Immun 70 (2002) 6330-6338
100. Kimura H., Suda A., Sakuma T., Tatsumi K., Kawakami Y., and Kuriyama T. Nocturnal oxyhemoglobin desaturation and prognosis in chronic obstructive pulmonary disease and late sequelae of pulmonary tuberculosis. Respiratory Failure Research Group in Japan?. Intern Med 37 (1998) 354-359
101. Morris C.D., Bird A.R., and Nell H. The haematological and biochemical changes in severe pulmonary tuberculosis?. Q J Med 73 (1989) 1151-1159
102. Sharma S.K., and Ahluwalia G. Effect of antituberculosis treatment on cardiopulmonary responses to exercise in miliary tuberculosis?. Indian J Med Res 124 (2006) 411-418
103. Farber J.L. Biology of disease: membrane injury and calcium homeostasis in the pathogenesis of coagulative necrosis?. Lab Invest 47 (1982) 114-123
104. Giachelli C.M. Vascular calcification: in vitro evidence for the role of inorganic phosphate?. J Am Soc Nephrol 14 (2003) S300-S304
105. Giachelli C.M. Vascular calcification mechanisms?. J Am Soc Nephrol 15 (2004) 2959-2964
106. Giachelli C.M., Speer M.Y., Li X., Rajachar R.M., and Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin?. Circ Res 96 (2005) 717-722
107. Kim K.M. Cells, rather than extracellular matrix, nucleate apatite in glutaraldehyde-treated vascular tissue?. J Biomed Mater Res 59 (2002) 639-645
108. Wu-Wong J.R., Noonan W., Ma J., Dixon D., Nakane M., Bolin A.L., Koch K.A., Postl S., Morgan S.J., and Reinhart G.A. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification?. J Pharmacol Exp Ther 318 (2006) 90-98
109. Basaraba R.J., Bielefeldt-Ohmann H., Eschelbach E.K., Reisenhauer C., Tolnay A.E., Taraba L.C., Shanley C.A., Smith E.A., Bedwell C.L., Chlipala E.A., and Orme I.M. Increased expressio of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig?. Tuberculosis (Edinb) 88 (2007) 69-70
110. Makowski G.S., and Ramsby M.L. Amorphous calcium phosphate-mediated binding of matrix metalloproteinase-9 to fibrin is inhibited by pyrophosphate and bisphosphonate?. Inflammation 23 (1999) 333-360
111. Gupta L.C., Singla S.K., Tandon C., and Jethi R.K. Mg2+: a potent inhibitor of collagen-induced in vitro mineralization?. Magnes Res 17 (2004) 67-71
112. Corper H.J. Founders of our knowledge of tuberculosis?. Hygeia October-November (1929) 1-13
113. Teng R., and Dick T. Isoniazid resistance of exponentially growing Mycobacterium smegmatis biofilm culture?. FEMS Microbiol Lett 227 (2003) 171-174
114. Yanagihara K., Tomono K., Sawai T., Kuroki M., Kaneko Y., Ohno H., Higashiyama Y., Miyazaki Y., Hirakata Y., Maesaki S., Kadota J., Tashiro T., and Kohno S. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation?. J Antimicrob Chemother 46 (2000) 69-72
115. Kirov S.M., Webb J.S., O'May C.Y., Reid D.W., Woo J.K., Rice S.A., and Kjelleberg S. Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis?. Microbiol 153 (2007) 3264-3274
116. Parsek M.R., and Singh P.K. Bacterial biofilms: an emerging link to disease pathogenesis?. Annu Rev Microbiol 57 (2003) 677-701
117. Prince A.S. Biofilms, antimicrobial resistance, and airway infection?. N Engl J Med 347 (2002) 1110-1111
118. Toney J.H. Biofilms - a neglected antibacterial target?. Curr Opin Investig Drugs 8 (2007) 598-599
119. Walker T.S., Tomlin K.L., Worthen G.S., Poch K.R., Lieber J.G., Saavedra M.T., Fessler M.B., Malcolm K.C., Vasil M.L., and Nick J.A. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils?. Infect Immun 73 (2005) 3693-3701
120. Whitchurch C.B., Tolker-Nielsen T., Ragas P.C., and Mattick J.S. Extracellular DNA required for bacterial biofilm formation?. Science 295 (2002) 1487
121. Chung M.J., Lee K.S., Koh W.J., Lee J.H., Kim T.S., Kwon O.J., and Kim S. Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between Myco-bacterium avium-intracellulare complex and Myco-bacterium abscessus infection?. J Korean Med Sci 20 (2005) 777-783
122. Hall-Stoodley L., and Lappin-Scott H. Biofilm formation by the rapidly growing mycobacterial species Mycobacterium fortuitum?. FEMS Microbiol Lett 168 (1998) 77-84
123. Ojha A., Anand M., Bhatt A., Kremer L., Jacobs Jr. W.R., and Hatfull G.F. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria?. Cell 123 (2005) 861-873
124. Primm T.P., Lucero C.A., and Falkinham III J.O. Health impacts of environmental mycobacteria?. Clin Microbiol Rev 17 (2004) 98-106
125. Saunders B.M., Orme I.M., and Basaraba R.J. Immunopathology of Tuberculosis. Handbook of Tuberculosis: Immunology and Cell Biology. 1 edn. (2008), Wiley-VCH Verlag GmbH & Co., Weinheim
126. Basaraba R.J., Smith E.E., Shanley C.A., and Orme I.M. Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol?. Infect Immun 74 (2006) 5397-5401
127. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., Birrer P., Bellon G., Berger J., Weiss T., Botzenhart K., Yankaskas J.R., Randell S., Boucher R.C., and Doring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients?. J Clin Invest 109 (2002) 317-325
128. Cronje L., Edmondson N., Eisenach K.D., and Bornman L. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions?. FEMS Immunol Med Microbiol 45 (2005) 103-112
129. De Voss J.J., Rutter K., Schroeder B.G., Su H., Zhu Y., and Barry III C.E. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages?. Proc Natl Acad Sci USA 97 (2000) 1252-1257
130. Luo M., Fadeev E.A., and Groves J.T. Mycobactin-mediated iron acquisition within macrophages?. Nat Chem Biol 1 (2005) 149-153
131. Reid D.W., Carroll V., O'May C., Champion A., and Kirov S.M. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis?. Eur Respir J 30 (2007) 286-292
132. Yeruva V.C., Duggirala S., Lakshmi V., Kolarich D., Altmann F., and Sritharan M. Identification and characterization of a major cell wall-associated iron-regulated envelope protein (Irep-28) in Mycobacterium tuberculosis?. Clin Vaccine Immunol 13 (2006) 1137-1142
133. Ojha A., and Hatfull G.F. The role of iron in Mycobacterium smegmatis biofilm formation: the exochelin siderophore is essential in limiting iron conditions for biofilm formation but not for planktonic growth?. Mol Microbiol 66 (2007) 468-483
134. Meyer D. Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload?. Curr Pharm Des 12 (2006) 1943-1947
135. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators?. Baillieres Clin Haematol 7 (1994) 965-1000
136. Banin E., Brady K.M., and Greenberg E.P. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm?. Appl Environ Microbiol 72 (2006) 2064-2069
137. Banin E., Vasil M.L., and Greenberg E.P. Iron and Pseudomonas aeruginosa biofilm formation?. Proc Natl Acad Sci U S A 102 (2005) 11076-11081
138. Kaneko Y., Thoendel M., Olakanmi O., Britigan B.E., and Singh P.K. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity?. J Clin Invest 117 (2007) 877-888
139. Lounis N., Maslo C., Truffot-Pernot C., Grosset J., and Boelaert R.J. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis?. Int J Tuberc Lung Dis 7 (2003) 575-579
140. Ulrichs T., Kosmiadi G.A., Jorg S., Pradl L., Titukhina M., Mishenko V., Gushina N., and Kaufmann S.H. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma?. J Infect Dis 192 (2005) 89-97
141. Balasubramanian V., Wiegeshaus E.H., Taylor B.T., and Smith D.W. Pathogenesis of tuberculosis: pathway to apical localization?. Tuber Lung Dis 75 (1994) 168-178
142. Sweany H.C., and Seiler H.H. The pathology and bacteriology of resected lesions in pulmonary tuberculosis?. Dis Chest 29 (1956) 119-152
143. Nelson M.E., O'Brien-Ladner A.R., and Wesselius L.J. Regional variation in iron and iron-binding proteins within the lungs of smokers?. Am J Respir Crit Care Med 153 (1996) 1353-1358
144. Ashitani J., Mukae H., Hiratsuka T., Nakazato M., Kumamoto K., and Matsukura S. Elevated levels of alpha-defensins in plasma and BAL fluid of patients with active pulmonary tuberculosis?. Chest 121 (2002) 519-526
145. Lurie M.B. The nature of the virulence of human and bovine types of tubercle bacilli for the rabbit?. Am Rev Tuberc 67 (1953) 265-266
146. Manabe Y.C., Dannenberg Jr. A.M., Tyagi S.K., Hatem C.L., Yoder M., Woolwine S.C., Zook B.C., Pitt M.L., and Bishai W.R. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis?. Infect Immun 71 (2003) 6004-6011
147. Kim T.S., Koh W.J., Han J., Chung M.J., Lee J.H., Lee K.S., and Kwon O.J. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thinsection CT and histopathologic correlation?. AJR Am J Roentgenol 184 (2005) 1247-1252
148. Kraft S.L., Dailey D., Kovach M., Stasiak K.L., Bennett J., McFarland C.T., McMurray D.N., Izzo A.A., Orme I.M., and Basaraba R.J. Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis?. Infect Immun 72 (2004) 5963-5971
149. Lurie M.B. Experimental epidemiology of tuberculosis: the effect of eliminating exposure of enteric infection on the incidence and course of tuberculosis acquired by normal guinea pigs confined with tuberculosis cage mates?. J Exp Med (1930) 753-768
150. Palanisamy GS, Smith EE, Shanley CA, Ordway DJ, Orme IM, Basaraba RJ. Disseminated disease severity as a measure of virulnece of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb) 2008, In Press.
151. Medina L.A., Calixto S.M., Klipper R., Phillips W.T., and Goins B. Avidin/biotin-liposome system injected in the pleural space for drug delivery to mediastinal lymph nodes?. J Pharm Sci 93 (2004) 2595-2608
152. Tsenova L., Mangaliso B., Muller G., Chen Y., Freedman V.H., Stirling D., and Kaplan G. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis?. Antimicrob Agents Chemother 46 (2002) 1887-1895
153. Johnson C.M., Pandey R., Sharma S., Khuller G.K., Basaraba R.J., Orme I.M., and Lenaerts A.J. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis?. Antimicrob Agents Chemother 49 (2005) 4335-4338
154. Roy E., Lowrie D.B., and Jolles S.R. Current strategies in TB immunotherapy?. Curr Mol Med 7 (2007) 373-386
155. Williams K.J., and Duncan K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB?. Curr Mol Med 7 (2007) 297-307